Agency News

Latest News | Wockhardt Approaches DCGI for Marketing Approval for Diabetes Drug

Get latest articles and stories on Latest News at LatestLY. Drug firm Wockhardt on Wednesday said it has approached the DCGI for marketing approval of a diabetes treatment medication.

Latest News | Wockhardt Approaches DCGI for Marketing Approval for Diabetes Drug

New Delhi, Oct 16 (PTI) Drug firm Wockhardt on Wednesday said it has approached the DCGI for marketing approval of a diabetes treatment medication.

The company has filed its fast-acting insulin analog, Aspart injection, with the Drugs Controller General of India (DCGI), the Mumbai-based drug firm said in a regulatory filing.

Also Read | Kolkata Fatafat Result Today: Kolkata FF Result for October 16, 2024 Declared, Check Winning Numbers and Result Chart of Satta Matka-Type Lottery Game.

"We are proud of adding another feather in our diabetes biosimilars portfolio through filing of insulin Aspart injection in a market that has limited competition," Wockhardt Founder Chairman Habil Khorakiwala said.

This reinforces the company's ability to develop and manufacture complex biosimilars domestically, he added.

Also Read | Shillong Teer Results Today, October 16 2024: Winning Numbers, Result Chart for Shillong Morning Teer, Shillong Night Teer, Khanapara Teer, Juwai Teer and Jowai Ladrymbai.

Wockhardt's Aspart insulin injection is an indigenously developed product, underscoring the company's end-to-end capabilities in research & development, clinical studies, scale up and manufacturing of biosimilars products.

The market size of Aspart in India is currently estimated at over Rs 260 crore with only two players and is expected to grow significantly in the coming years.

Diabetes remains a critical health issue, affecting more than 77 million people in India and over 537 million people worldwide and is expected to be over 643 million by 2030.

The prevalence of diabetes is rising sharply, driven by lifestyle changes, aging population, and urbanisation.

Wockhardt said it is also developing additional insulin analogs and GLP-1 agonists as part of its comprehensive strategy to provide advanced diabetes care solutions.

The introduction of these products will further strengthen Wockhardt's diabetes portfolio, offering patients more effective treatment options for managing their condition, it added.

Shares of Wockhardt were trading 1.34 per cent up at Rs 1,095 apiece on BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)